Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.
Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.
AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.
Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.
The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.
Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.
In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.
High-quality cytokines for organoid growth, differentiation, and expansion
At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.
PRESS RELEASES
Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT
• Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestones • Company expects to complete early market access regulatory approval submissions for Herlystic™ (“OST-HER2" or “daznelimgene lisbac”) in the U.S., U.K., Europe and Australia in the fourth quarter of 2026
New facility in Namie will leverage NovAccel’s proprietary compact superconducting accelerator technology to support reliable, commercial-scale Ac-225 production